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Peripapillary Choroidal Thickness Change of Polypoidal Choroidal 
Vasculopathy after Anti-vascular Endothelial Growth Factor
Kyou Ho Lee, Seo Hee Kim, Ji Min Lee, Eui Chun Kang, Hyoung Jun Koh
Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea
Purpose: To investigate the peripapillary choroidal thickness (PCT) of polypoidal choroidal vasculopathy (PCV) 
and exudative age-related macular degeneration (AMD) and to evaluate their responses to anti-vascular en-
dothelial growth factor (VEGF).
Methods: Thirty eyes with PCV and 25 eyes with exudative AMD who were treatment naïve were included in 
this study. PCT and subfoveal choroidal thickness were evaluated both before and after intravitreal anti-VEGF.
Results: The initial mean PCT of PCV (153.78 ± 56.23 µm) was thicker than that of exudative AMD (88.77 ± 
23.11 µm, p < 0.001). Temporal, superior, nasal, and inferior PCTs of PCV were all thicker than those observed 
in exudative AMD (all p < 0.05). After anti-VEGF, the mean PCT of PCV was significantly reduced (134.17 ± 
41.66 µm, p < 0.001), but the same was not true not in exudative AMD (86.87 ± 22.54 µm, p = 0.392). PCT 
showed a similar tendency in all quadrants.
Conclusions: PCV exhibits a thick choroid in the peripapillary region. PCT decreases after anti-VEGF in PCV 
but not in exudative AMD. In exudative AMD, subfoveal choroidal thickness decreased, but that in the peripap-
illary region did not.
Key Words: Anti-vascular endothelial growth factor, Choroid, Macular degeneration, Polypoidal choroidal vas-
culopathy
Polypoidal choroidal vasculopathy (PCV) was originally 
described as a retinal disorder characterized by abnormali-
ties of the choroidal vasculature, including the inner 
branching vascular networks, terminating in polypoidal le-
sions that can be seen on indocyanine green angiography 
(ICGA) [1]. PCV has been considered a variant of exuda-
tive age-related macular degeneration (AMD) because of 
their phenotypic similarities [2], but PCV and exudative 
AMD have differences in ethnic prevalence, natural histo-
ry, and treatment responses [3-5]. These differences sug-
gest that PCV and exudative AMD are two distinct diseas-
es, with PCV being a primary abnormality of the choroid 
[6].
It is increasingly being observed that PCV has a thick 
subfoveal choroid [7-9]. Recently, several studies have re-
ported that the subfoveal choroid is thicker in eyes with 
PCV than in those with typical exudative AMD [7-9], and 
that the subfoveal choroid is thicker in eyes with PCV with 
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choroidal vascular hyperpermeability, suggesting different 
pathological mechanisms in PCV and exudative AMD [10]. 
It has been proposed that pachychoroid neovasculopathy, 
including pachychoroid pigment epitheliopathy, central se-
rous chorioretinopathy, and PCV, is caused by a pachycho-
roid-driven process involving choroidal congestion and 
choroidal hyperpermeability manifested by choroidal 
thickening and dilated choroidal vessels [11,12].
However, current studies on the choroidal thickness (CT) 
of PCV have been limited to the choroid of the macular re-
gion. Therefore, it is unclear whether the increased CT in 
patients with PCV is a general characteristic of the choroid 
or a localized phenomenon limited to the macula. Because 
the choroid is supplied by various capillary arteries ac-
cording to regional distribution, the CT outside the macula, 
especially that in the peripapillary region, might reflect a 
different PCV pathophysiology. We therefore hypothesized 
that PCV has a different peripapillary choroidal thickness 
(PCT) and anti-vascular endothelial growth factor (anti-
VEGF) response than exudative AMD. In the following 
study, we retrospectively investigated PCT and its response 
to anti-VEGF in eyes with PCV and exudative AMD.
Materials and Methods
This retrospective, comparative series was approved by 
the institutional review board of Yonsei University, Seoul, 
South Korea. Informed consent was obtained from all pa-
tients, and all study protocols adhered to the tenets of the 
Declaration of Helsinki. All data were collected from the 
Department of Ophthalmology, Severance Hospital, and 
all participants underwent a comprehensive ophthalmic 
examination, including measurement of best-corrected vi-
sual acuity, a dilated fundus examination, fundus fluores-
cein angiography, and ICGA with spectral domain optical 
coherence tomography (Spectralis OCT, ver. 1.5.12.0; Hei-
delberg Engineering, Heidelberg, Germany).
We retrospectively reviewed the medical records of pa-
tients with PCV or exudative AMD from January 2012 to 
June 2014. Inclusion criteria were as follows: (1) treatment 
for naïve PCV or exudative AMD, (2) more than 6 months 
of follow-up with anti-VEGF treatment (three consecutive 
monthly injections followed by a pro re nata protocol), and 
(3) optical coherence tomography (OCT) scan images of 
the peripapillary and macula regions at the initial visit and 
at the 6-month follow-up visit. Exclusion criteria included 
the presence of refractive errors >±3.0 diopters, amblyopia, 
significant cataract, obscuration of choroidal images due to 
the existence of significant media opacity or thick subfove-
al hemorrhage, central geographic atrophy, a history of oc-
ular inflammation, a history of retinal detachment, previ-
ous vitrectomy, intraocular surgery (including cataract 
surgery) in the study eye within 1 year, a history of ocular 
trauma, and glaucoma in the study eye. Eyes that under-
went photodynamic therapy were also excluded.
PCV was diagnosed primarily on the basis of ICGA 
findings, branching vascular networks, and terminating 
polypoidal lesion(s). The diagnosis of exudative AMD was 
based on a combination of fundus fluorescein angiography 
and ICGA according to hyperfluorescence with late leak-
age associated with pigment epithelial detachment in the 
macular region, serous retinal detachment, subretinal exu-
dation, or hemorrhage [13].
Measurement of peripapillary and macular CT 
The peripapillary area was defined as the area within 3.4 
mm from the center of the optic disk. CT was set as the 
vertical distance from the hyperreflective line of Bruch’s 
membrane to the innermost hyperref lective line of the 
sclerochoroidal interface. A 360°, 3.4-mm-diameter circu-
lar OCT scan used the standard protocol for retinal nerve 
fiber layer assessment. Each sector was measured 90° from 
the temporal area, clockwise in the right eye and counter 
clockwise in the left eye (Fig. 1A-1F, 2A-2L). Thus, the 0° 
area of both eyes indicated the temporal peripapillary area, 
and the 90°, 180°, and 270° areas corresponded to the supe-
rior, nasal, and inferior PCT, respectively. PCT was mea-
sured using a previously reported method [14]. Briefly, us-
ing the modif ication tool in the OCT image viewer 
program, the segmentation line indicating the retinal pig-
ment epithelium was modified to the sclerochoroidal junc-
tion by the investigator. With this modification, the chorio-
retinal thickness between the internal limiting membrane 
and the sclerochoroidal junction was measured. The CT 
was calculated by subtracting the retinal thickness from 
the chorioretinal thickness at each quadrant (Fig. 1). Mea-
surement of subfoveal CT on the line scan image was per-
formed manually with a built-in caliper tool in the OCT 
viewer program. Subfoveal CT was measured at the center 
of the fovea. If the retinal pigment epithelium line was not 
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clearly defined because of pigment, epithelial detachment, 
or other abnormalities, Bruch’s membrane was used as the 
inner margin of the choroid. If a hyporeflective band rep-
resenting a suprachoroidal layer was seen on OCT, it was 
not included in the CT [15]. In cases with poorly defined 
chorioscleral junctions, the outer choroidal margin was de-
marcated as the line connecting the outer margin of the 
large choroidal vessel layer. Peripapillary and subfoveal 
OCT images were obtained at the initial presentation and 
again 6 months after anti-VEGF treatment. All measure-
ments were performed by two independent observers 
(SHK and JML) in a blinded fashion, and the mean of 
these observations was used for analyses.
Statistical analyses
The baseline characteristics between PCV and exudative 
AMD were compared using chi-square tests for categorical 
variables and independent t-tests for continuous variables. 
All comparisons between PCV and exudative AMD were 
adjusted by age using an analysis of covariance. A paired 
t-test was carried out to compare results before and after 
anti-VEGF treatment in each group. A one-way analysis of 
variance test was used to determine possible differences 
between the sectors of the PCT. The reproducibility of CT 
measurements between the observers was calculated via 
intraclass correlation coefficients. All statistical analyses 
were performed using SPSS ver. 20.0 for Windows (IBM 
Corp., Armonk, NY, USA). A p-value <0.05 was consid-
ered statistically significant.
Results
Thirty eyes with PCV and 25 exudative eyes with AMD 
were included in this study. The mean age of the PCV pa-
tients was 6.63 years younger than that of the exudative 
AMD patients (69.17 ± 7.78 and 73.80 ± 8.06 years, respec-
tively, p = 0.038). There was no difference in other baseline 
characteristics, such as history of diabetes mellitus or hy-
pertension, sex, lens status, or refractive error, between the 
PCV and the exudative AMD patients (Table 1).
Anti-VEGF treatment 
The initial treatment agents were bevacizumab and ran-
ibizumab. Two cases in each PCV and exudative AMD 
groups switched agent during the 6-month follow-up peri-
Fig. 1. Measurement of peripapillary cho-
roidal thickness and subfoveal choroidal 
thickness. (A) Fundus photography of a 
56-year-old female with polypoidal choroi-
dal vasculopathy. (B,D) We measured the 
peripapillary choroidal thickness by sub-
tracting the retinal thickness (D) from the 
chorioretinal thickness obtained by manual 
modification of the retinal pig ment epithe-
lium line (B). (C) A 360° 3.4-mm-diameter 
circle scan around the disc was performed to 
obtain the retinal and choroidal thickness. (E) 
Horizontal scan line of fundus. (F) Subfoveal 
choroi dal thickness. ILM = internal limiting 
membrane; SC = sclerochoroidal junction; T 
= temporal; S = superior, N = nasal; I = infe-
rior; BM = Bruch’s membrane. 
A
C
E
B
D
F
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od (Table 2).
Peripapillary choroidal thickness 
The initial PCT of PCV was thicker than that seen in ex-
udative AMD. All quadrants showed a similar tendency 
(all p < 0.001). The mean initial PCT of PCV was 1.73-fold 
thicker than that of exudative AMD, and the difference 
between PCV and exudative AMD was 65.01 µm ( p < 
0.001). The initial PCT difference was largest in the supe-
rior quadrant and lowest in the inferior quadrant (77.11 µm 
and 49.03 µm, respectively). The initial inferior PCT of 
PCV was thinner than those in the temporal and superior 
quadrants (p = 0.018 and p = 0.015, respectively) but not 
thinner than that of the nasal quadrant (p = 0.09). The ini-
tial inferior PCT of exudative AMD was thinner than 
those of the superior and nasal quadrants (p = 0.014 and p 
= 0.012, respectively) but not thinner than that of the tem-
poral quadrant (p = 0.105) (Fig. 3). 
After anti-VEGF treatment, the mean PCT of the PCV 
decreased by 12.75%, from 154.78 ± 56.23 µm to 134.17 ± 
41.66 µm (p < 0.001). The PCT of the PCV after treatment 
of all quadrants showed a similar tendency (Fig. 3). The 
PCT reduction in PCV was greatest in the inferior quad-
rant and lowest in the superior quadrant (18.94%, 22.67 µm 
and 10.23%, 17.27 µm, respectively). However, in exudative 
AMD, there was no statistically significant difference fol-
lowing anti-VEGF treatment. The mean PCT of exudative 
AMD after treatment decreased by 2.14% from 88.77 ± 
23.11 µm to 86.87 ± 22.54 µm (p = 0.392). The PCT reduc-
tion in exudative AMD was greatest in the superior quad-
rant and lowest in the nasal quadrant, but no quadrant dif-
ferences were signif icant ( p = 0.23 and p = 0.948, 
respectively) (Table 3). Although the PCT of PCV de-
creased more than that of exudative AMD after treatment, 
the mean PCT of PCV was still thicker (1.53-fold) than that 
of exudative AMD, and the difference between PCV and 
exudative AMD was 47.3 µm (p < 0.001). The inferior PCT 
was also thinner than those of the other quadrants in both 
PCV and exudative AMD after treatment (p = 0.03 and p 
< 0.001, respectively). There was no difference in response 
between the types of anti-VEGFs.
Subfoveal choroidal thickness
The initial subfoveal CT of PCV was 128.35 µm, which 
was 1.75-fold thicker than that of exudative AMD (p < 
0.001). After anti-VEGF treatment, both the subfoveal CT 
of PCV and exudative AMD were reduced (p < 0.001 and 
p = 0.021, respectively). However, the percentage reduction 
was greater in PCV than in exudative AMD (59.56 µm, 
19.85% and 15.56 µm, 9.06%, respectively). The difference 
also decreased; the mean subfoveal CT of PCV after treat-
ment was still thicker (1.54-fold) than that of exudative 
AMD, and the difference between PCV and exudative 
Table 2. Anti-vascular endothelial growth factor treatment for PCV and exudative AMD
PCV (n = 30)  Exudative AMD (n = 25) Total 
Initially treated with bevacizumab 17 10 27
Initially treated with ranibizumab 11 13 24
Switched to another agent  2  2  4
PCV = polypoidal choroidal vasculopathy; AMD = age-related macular degeneration.
Table 1. Baseline characteristics of patients with PCV and 
exudative AMD
PCV
Exudative 
AMD
p-value
No. of eyes 30 25 -
Age (yr) 69.17 ± 7.78 73.80 ± 8.06  0.038
Male : female   16 : 14 10 : 15  0.419
Involved eye 
(OD : OS) 14 : 16 11 : 14 >0.999
Lens (phakic) 25 (83.3) 19 (76) 0.521
DM 4 (13.3) 3 (12) >0.999
HTN 15 (50) 16 (64) 0.414
Refraction, SE (D) 0.15 ± 1.44 0.16 ± 1.35 0.997
Values are presented as mean ± standard deviation or number (%).
PCV = polypoidal choroidal vasculopathy; AMD = age-related 
macular degeneration; OD = right eye; OS = left eye; DM = dia-
betes mellitus; HTN = hypertension; SE = spherical equivalent; 
D = diopters.
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AMD was 84.35 µm (Table 3). There was also no differ-
ence in response according to type of anti-VEGF.
In terms of interobserver reproducibility, the intraclass 
correlation coefficients showed agreement between the 
two observers in all locations both initially and after treat-
ment (p < 0.001). These values were high and ranged from 
0.903 to 0.953. 
Discussion
Our results showed that all quadrants of PCT in PCV 
were larger than those of exudative AMD and were re-
duced after anti-VEGF treatment. The PCT of exudative 
AMD showed no difference after anti-VEGF treatment. 
Inferior PCT was thinner than all other quadrants in both 
PCV and exudative AMD before and after anti-VEGF 
treatment. The initial mean PCT was 1.73-fold thicker in 
Table 3. A comparison of PCT between PCV and exudative AMD both before and after anti-VEGF treatment
Before Treatment After Treatment
PCV Exudative AMD p-value PCV Exudative AMD
p-value
PCV Exudative AMD
Mean PCT (µm) 153.78 ± 56.23 88.77 ± 23.11 <0.001 134.17 ± 41.66 86.87 ± 22.54 <0.001 0.392
Temporal PCT (µm) 167.83 ± 70.69 90.72 ± 27.16 <0.001 149.70 ± 57.29 90.52 ± 29.64  0.022 0.948
Superior PCT (µm) 168.80 ± 59.05 96.64 ± 38.19 <0.001 151.53 ± 46.31 91.04 ± 32.34  0.006 0.231
Nasal PCT (µm) 158.83 ± 64.43 97.08 ± 28.61 <0.001 138.47 ± 52.94 98.00 ± 28.54 <0.001 0.790
Inferior PCT (µm) 119.67 ± 49.67 70.64 ± 20.92 <0.001  97.00 ± 38.26  67.92 ± 20.90 <0.001 0.302
Subfoveal (µm)  300.03 ± 108.00 171.68 ± 56.92 <0.001 240.47 ± 41.66 156.12 ± 64.56 <0.001 0.021
Values are presented as mean ± standard deviation.
PCT = peripapillary choroidal thickness; PCV = polypoidal choroidal vasculopathy; AMD = age-related macular degeneration; VEGF = 
vascular endothelial growth factor.
Fig. 2. A representative case of the change 
in peripapillary choroidal thickness (PCT) 
following administration of anti-vascular en-
dothelial growth factor (VEGF) in polypoidal 
choroidal vasculopathy (PCV) and exudative 
age-related macular degeneration (AMD). 
(A-F) A 70-year-old female with PCV. (B,C) 
The subfoveal choroidal thickness decreased 
from 407 µm to 303 µm. (E,F) The mean PCT 
was 198 µm and decreased to 150 µm after 
anti-VEGF administration (25%). (G-L) A 
77-year-old female with exudative AMD. (H,I) 
The subfoveal choroidal thickness decreased 
from 190 µm to 175 µm (K,L). The mean PCT 
values were 119 µm before and 114 µm after 
anti-VEGF.
A
D
G
J
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PCV than it was for exudative AMD. These differences 
decreased by 1.53-fold after anti-VEGF treatment. The 
mean PCT of PCV decreased by 12.75% after anti-VEGF 
treatment (p < 0.001), while that of exudative AMD de-
creased 2.14% (p = 0.392). These results suggest that cho-
roidal thickening in eyes with PCV is not a localized phe-
nomenon limited to the macular area, but is rather a 
general characteristic extending to the peripapillary area 
outside the macula. 
The blood supply of the choroid region is complicated 
and can be influenced by many local factors. The vortex 
vein, ciliary vascular supply, and any bypasses of peripap-
illary circulation also have an effect on choroidal blood 
supply. However, the choroid is supplied by various capil-
lary arteries in a relatively distinctive pattern. The nasal 
choroid is fed by the medial posterior ciliary artery (PCA), 
whereas the lateral PCA supplies the area of the choroid 
not supplied by the medial PCA [16]. The posterior chorio-
capillaris in the peripapillary and submacular regions are 
fed by short PCAs. The PCA from the ophthalmic artery 
supplies the choroid around the optic nerve head and also 
supplies the choroid up to the equator [16]. Usually, the 
temporal half of the choroid is supplied by the lateral PCA, 
and the nasal half of the choroid is supplied by the medial 
PCA [16]. The branches of the PCA consist of long PCAs 
and short PCAs. The temporal short PCAs, which arise 
from the lateral PCA, enter the eyeball in the macular re-
gion and supply the macular choroid [16]. Because there 
are no anastomoses between the long PCAs and the short 
PCAs, there are watershed zones between the areas that 
are supplied by both [16-19]. They have a segmental distri-
bution without anastomoses and supply a well-defined sec-
tor of the choroid [17,19,20].
Our results suggest that the pathophysiology of PCV is 
related to the entire blood supply to the choroid, rather 
than being confined only to the focal choroidal vascular 
abnormality. In addition, the pathogenesis of exudative 
AMD may be relatively restricted to the macular area and 
focal chorioretinal abnormalities because thickening of the 
choroid may be associated with the anatomy and circulato-
ry characteristics of the eye [21-23]. The choroid in the 
macula is somewhat different from the choroid of other ar-
eas. The blood supply to the choroid of the macula has two 
origins involving branches of the short PCAs and a recur-
rent branch of the long PCA [24]. The presence of very 
short PCAs selectively directed to the macular region, has 
been confirmed by previous studies [24]. Very short PCAs 
may contribute to subfoveal CT and are thought to be re-
lated with the development of PCV. 
Our finding that the CT decreases in the peripapillary 
region after anti-VEGF treatment may be another indica-
tion of the diffuse choroidal abnormality of PCV. Com-
pared to exudative AMD, PCV has been reported to occur 
in patients with thick subfoveal choroids [11,12]. Yamazaki 
et al. [25] examined the changes in subfoveal CT after in-
travitreal injections of ranibizumab for unilateral exuda-
tive AMD and PCV. Their results suggested that intravit-
real injections of ranibizumab have a pharmacological 
effect not only on the neovascular lesion, but also on the 
thickened underlying choroid. Other studies have also re-
ported that an abnormally thickened choroid decreased af-
ter anti-VEGF treatment [26,27]. In contrast to PCV, PCT 
of exudative AMD did not change after anti-VEGF treat-
ment, suggesting that diffuse choroidal thickening is asso-
ciated with the pathogenesis of PCV, and that choroidal 
thinning, such as vortex decompression, may help to re-
duce polyp development. 
Our results confirmed the asymmetrical distribution of 
Fig. 3. Change in peripapillary choroidal thickness (PCT) in pol-
ypoidal choroidal vasculopathy (PCV) and exudative age-related 
macular degeneration (AMD). The PCT of PCV was thicker than 
that of exudative AMD both before and after anti-vascular endo-
thelial growth factor (VEGF) was administered. PCT decreased 
after anti-VEGF in PCV (*p < 0.022) but not in exudative AMD. 
Inferior PCT was thinnest in both PCV and exudative AMD both 
before and after anti-VEGF. †p < 0.018 with post hoc analysis 
between the sectors of PCV before treatment; ‡p < 0.014 with 
post hoc analysis between the sectors of exudative AMD before 
anti-VEGF.
Temporal Superior Nasal
Exudative AMD
after anti-VEGF
Inferior
210
190
170
150
130
110
90
70
50
⁎
†,‡ †,‡ †,‡ 
†,‡ 
⁎
⁎
⁎
PC
T 
(µ
m)
PCV
PCV after anti-VEGF 
Exudative  AMD
437
KH Lee, et al. Peripapillary Choroidal Thickness in PCV
the PCT. The mean PCT showed regional differences and 
was thickest in the superior region and thinnest in the infe-
rior region in both PCV and exudative AMD. These results 
are similar to previous OCT studies in normal eyes, which 
have consistently shown the inferior region to be thinner 
than other regions [28-30]. The thinner choroid in the infe-
rior region makes this area more vulnerable to retinal and 
choroidal disorders. Several studies have hypothesized that 
the thinnest peripapillary choroid in the inferior quadrant 
may involve an area of lower blood supply that may pre-
dispose the inferior region of the optic nerve to glaucoma-
tous ischemic damage, supporting a possible explanation 
for the well-known observation that glaucoma typically 
affects the inferior optic nerve region first [28,31].
A recent study compared changes in subfoveal and peri-
papillary CT after intravitreal aflibercept or ranibizumab 
injections in 54 treatment-naïve patients with exudative 
AMD [32]. They discovered intravitreally injected afliber-
cept significantly decreased subfoveal CT more than ra-
nibizumab. Additionally, choroidal thinning after afliber-
cept injection was not limited to the subfoveal area, but 
instead extended beyond the macula to the peripapillary 
region. However, we could not find any differences be-
tween bevacizumab and ranibizumab. The shape, molecu-
lar weight, or mechanism of the antibody may affect the 
power to reduce CT. Therefore, the effects of different 
types of anti-VEGF drugs should be evaluated in future 
studies. 
To the best of our knowledge, this is the first study to in-
vestigate the PCT in PCV and exudative AMD and the ef-
fects of anti-VEGF treatment in the peripapillary region. 
However, this study had several limitations. First, it was a 
retrospective study; a comparison with a normal control 
group was not conducted, and diurnal variations of the CT 
were not considered [33]. Second, although we compared 
two groups adjusted for age, the baseline characteristics 
and types and numbers of anti-VEGF treatments were not 
controlled. Third, because the peripapillary choroid was 
thin and the CT measurement was performed manually, 
the accuracy of measurements was limited. Fourth, previ-
ous studies on choroidal hyperpermeability in PCV eyes 
reported that choroidal thickening might depend on cho-
roidal vascular hyperpermeability [10]. Additional study 
will be needed to investigate the relationship between in-
creased CT and choroidal hyperpermeability.
In conclusion, eyes with PCV exhibited a thick choroid 
overall in both the peripapillary and macula regions. Both 
regions decreased in thickness after anti-VEGF treatment 
in PCV but not in eyes with exudative AMD. In eyes with 
exudative AMD, subfoveal CT decreased, but the peripap-
illary region did not. The results of this study increased 
our understanding of the pathogenesis of PCV and may 
provide a basis for the development of new treatments for 
this disorder.
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